Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    12242449 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
Condition: Metastatic Cancer
Interventions: Biological: PG13-CEA_TCR (Anti-CEA TCR PBL);   Drug: Aldesleukin
2 Recruiting CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Large Cell Lymphoma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-CD19-CAR PBL
3 Terminated
Has Results
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
Condition: Melanoma
Interventions: Biological: ALVAC-MART-1 vaccine;   Biological: MART-1:26-35(27L) peptide vaccine;   Biological: Aldesleukin;   Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes;   Biological: incomplete Freund's adjuvant

Indicates status has not been verified in more than two years